Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab

References

• CongdonNO’ColmainBKlaverCCEye Diseases Prevalence Research GroupCauses and prevalence of visual impairment among adults in the United StatesArch Ophthalmol2004122447748515078664
   PubMed Web of Science ®Google Scholar
• BunceCWormaldRLeading causes of certification for blindness and partial sight in England & WalesBMC Public Health200665816524463
   PubMed Web of Science ®Google Scholar
• BresslerNMBresslerSBFineSLAge-related macular degenerationSurv Ophthalmol19883263754132457955
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• ModiYSTanchonCEhlersJPComparative safety and tolerability of anti-VEGF therapy in age-related macular degenerationDrug Saf201538327929325700714
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMANCHOR Study GroupRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
   PubMed Web of Science ®Google Scholar
• MuetherPSHermannMMDrögeKKirchhofBFauserSLong-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degenerationAm J Ophthalmol2013156598999323938122
   PubMed Web of Science ®Google Scholar
• FauserSSchwabeckerVMuetherPSSuppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degenerationAm J Ophthalmol2014158353253624879948
   PubMed Web of Science ®Google Scholar
• Seguin-GreensteinSLightmanSTomkins-NetzerOA meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age-related macular degeneration following switching to treatment with afliberceptJ Ophthalmol20162016409585227042342
   PubMed Web of Science ®Google Scholar
• BakallBFolkJCBoldtHCAflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumabAm J Ophthalmol201315611522.e123706500
   PubMed Web of Science ®Google Scholar
• PelliDGRobsonJGWilkinsAJThe design of a new letter chart for measuring contrast sensitivityClin Vis Sci19882187199
   Google Scholar
• WoodJMOwensDAStandard measures of visual acuity do not predict drivers’ recognition performance under day or night conditionsOptom Vis Sci200582869870516127335
   PubMed Web of Science ®Google Scholar
• ElliottDBSandersonKConkeyAThe reliability of the Pelli-Robson contrast sensitivity chartOphthalmic Physiol Opt199010121242330208
   PubMed Web of Science ®Google Scholar
• MäntyjärviMLaitinenTNormal values for the Pelli-Robson contrast sensitivity testJ Cataract Refract Surg200127226126611226793
   PubMed Web of Science ®Google Scholar
• ThayaparanKCrosslandMDRubinGSClinical assessment of two new contrast sensitivity chartsBr J Ophthalmol200791674975217166891
   PubMed Web of Science ®Google Scholar
• RubinGSBandeen-RocheKHuangGHThe association of multiple visual impairments with self-reported visual disability: SEE projectInvest Ophthalmol Vis Sci2001421647211133849
   PubMed Web of Science ®Google Scholar
• FletcherDCSchuchardRAVisual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuityOptom Vis Sci200683317818916534460
   PubMed Web of Science ®Google Scholar
• BellmannCUnnebrinkKRubinGSMillerDHolzFGVisual acuity and contrast sensitivity in patients with neovascular age-related macular degeneration. Results from the Radiation Therapy for Age-Related Macular Degeneration (RAD-) StudyGraefes Arch Clin Exp Ophthalmol20032411296897413680248
   PubMed Web of Science ®Google Scholar
• CsakyKGRichmanEAFerrisFLReport from the NEI/FDA ophthalmic clinical trial design and endpoints symposiumInvest Ophthalmol Vis Sci200849247948918234989
   PubMed Web of Science ®Google Scholar
• HolladayJTProper method for calculating average visual acuityJ Refract Surg19971343883919268940
   PubMed Web of Science ®Google Scholar
• OwsleyCContrast sensitivityOphthalmol Clin North Am200316217117712809156
   PubMedGoogle Scholar
• MonésJRubinGSContrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degenerationEye (Lond)200519111142115015467700
   PubMed Web of Science ®Google Scholar
• PauleikhoffDNeovascular age-related macular degeneration: natural history and treatment outcomesRetina20052581065108416340538
   PubMed Web of Science ®Google Scholar
• WykoffCCBrownDMMaldonadoMECroftDEAflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)Br J Ophthalmol201498795195524518078
   PubMed Web of Science ®Google Scholar
• BarthelmesDCampainANguyenPFight Retinal Blindness! Project InvestigatorsEffects of switching from ranibizumab to afliber-cept in eyes with exudative age-related macular degenerationBr J Ophthalmol2016100121640164526994110
   PubMed Web of Science ®Google Scholar
• ChangAABroadheadGKHongTIntravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration: 12-month safety and efficacy outcomesOphthalmic Res2015552849026637166
   PubMed Web of Science ®Google Scholar
• YuzawaMFujitaKWittrup-JensenKUImprovement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degenerationOphthalmology2015122357157825439429
   PubMed Web of Science ®Google Scholar